My screener picked up on these tickers as well as a couple of others but all of these are focused in the medical sector.

MDGS  Medigus Ltd.

Prev   Close     $ 1.51     High     $ 2.45     % G/ L     +27.15%
Intra   Close    $ 1.92     Low      $ 1.67      $  G/ L     +$0.41                                        
AH      Close    $ 1.77

52WH              $ 4.19    23 NOV  2020
52WL               $ 1.22    04 SEP   2020

Volume        152.40M     
Float               23.78M

     This company has signed a LOI for controlling interest in an electronics wholesale distributor. Medigus, a medical device company is focused on technology and is in a few industries such as medical, internet tech and electric vehicles. MDGS owns about 33% of a company called Polyrizon which has recently had positive results with a gel to combat viruses like COVID-19 and other pathogens. Polyrizon's success was the catalyst for the MDGS 27% gain. Unfortunately, this one spiked in pre-market, dipped, hit its HOD minutes after market open and then trailed off around 10:45. Personally not looking to jump into this one but I could see this one retracing back to $2.15-30.

 
CYCN  Cyclerion Therapeutics Inc.

Prev   Close     $ 3.60     High     $ 4.23     % G/ L     +14.72%
Intra   Close     $ 4.13     Low      $ 3.60     $  G/ L     +$0.53
AH      Close     $ 4.11  

52WH              $ 8.96    18 SEP    2020
52WL               $ 2.08    03 MAY  2021

Volume            3.90M                             
Float              33.00M

     CYCN is another play that seems to have already ran its course. Cyclerion is a medical play in the field of Alzheimer’s. The catalyst for this company is the announcement of a presentation it will be making at the Alzheimer’s Association International Conference 2021 (AAIC), taking place July 26-30, 2021. This coupled with the institutional and insider purchases of shares totaling around $7.5M in Q2-2021 seems to have spurred confidence in retail investors that culminated in a nearly 15% run up today. My reason for hesitation is that it ran up to $4.80 in AH on Thursday and then crashed to its day low around 10:10 on Friday. It slowly clawed its way back to $4.23 before tapering off into the close, we'll see.

TLSA   Tiziana Life Sciences plc

Prev   Close    $ 1.81     High    $ 2.25      % G/ L     +14.05%
Intra   Close    $ 2.07    Low     $ 1.76       $  G/ L     +$0.26
AH      Close    $ 2.14

52WH             $12.17        31 JUL 2020
52WL               $ 1.73       20 JUL 2021

Volume          3.30M
Float            25.35M

     Tiziana is another medical play that has at least one analyst projecting a price target of $7.75-$8.00. Their reasoning could be based on the companies anticipated take home drug to combat COVID-19. TLSA is currently en route to starting a Phase II study of their new drug which will take place in Brazil and will be administered to more than 75 patients. From about noon to 2PM Friday Tiziana Life Sciences gained about 28% before dipping $0.25 only to bounce back immediately in AH. Although its 52WH is currently $12.17, it will soon drop to around $5.55 making way for traders to be eager to look for the breakout to occur sooner rather than later. We'll see where this goes over the next few weeks.


IMV      ImmunoVaccine Technologies Inc.

Prev  Close         $ 1.38    High     $ 1.89     % G/ L     +18.12%
Intra  Close         $ 1.63    Low      $ 1.38     $  G/ L    +$ 0.25
AH     Close         $ 2.65

52WH                  $ 5.73   05 AUG  2020
52WL                   $ 1.31    19  JUL    2021

Volume               16.60M
Float                   82.08M

     A cancer treatment company that uses therapies to activate the immune system to enable the body to fight off the deadly disease. As far as a catalyst goes there isn't much by way of, there is now a cure for one of the more deadly diseases on the planet. However, IMV did have a public offering of about 14.3M shares at a price of $1.75 per share which has since been closed. The price target for this stock has a very wide range from $2.00 to $10.00 with Wells Fargo projecting an astonishing $14.00. Could it hit these targets in the short term? Of course, but it doesn't seem likely. Friday, IMV hovered around its 52WL before dipping down a bit and then exploding in AH to an amazing $3.00 and then settling at $2.65.


NAOV  NanoVibronix Inc.

Prev  Close        $ 0.75    High     $ 2.72     % G/ L     +248.14%
Intra  Close        $ 2.61    Low      $ 0.71      $  G/ L     +$  1.86
AH     Close        $ 2.86

52WH                 $ 2.72    23 JUL 2021
52WL                  $ 0.54   18 SEP 2020

Volume           133.40M
Float                   4.36M

     The big news for NanoVibronix is that The Journal of Medical & Surgical Urology is publishing an article with overwhelmingly positive findings from a study of patients that used its UroShield in real world settings. On Friday beginning at 1PM, NAOV moved up an amazing 248% and another eight in aftermarket trading. With this ticker exceeding its previous 52WH by about two weeks, the next ceiling could be at $2.95 to $3.40. There isn't a lot of feedback for this stock other than small pockets of support on various social platforms. This a good time to be cautiously optimistic. Personally, it teeters on the edge of my comfort zone so it is one to watch for the first hour of trading before jumping in.